Ligand Pharmaceuticals LGND Increase (Decrease) in Income Taxes Receivable
Increase (Decrease) in Income Taxes Receivable at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInIncomeTaxesReceivable.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's increase (decrease) in income taxes receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's increase (decrease) in income taxes receivable?
- Ligand Pharmaceuticals (LGND) reported increase (decrease) in income taxes receivable of -$695K in Q1 2026.
- How has Ligand Pharmaceuticals's increase (decrease) in income taxes receivable changed year-over-year?
- Ligand Pharmaceuticals's increase (decrease) in income taxes receivable decreased by 107.5% year-over-year, from -$335K to -$695K.
- What is the long-term trend for Ligand Pharmaceuticals's increase (decrease) in income taxes receivable?
- Over 3 years (2021 to 2024), Ligand Pharmaceuticals's increase (decrease) in income taxes receivable has grown at a -16.6% compound annual growth rate (CAGR), from $3.98M to -$2.31M.